Table 3.
Characteristics and outcomes of clinical trials evaluated the effects of mobile apps in MASLD.
| APP | Author | Study duration | Participants (n) | Used app (n) | Comparator arm (n) | Strategy used for treatment | Effect | Ref |
|---|---|---|---|---|---|---|---|---|
| SMART-Liver | Kwon et al. | 26-Week | Patients with NAFLD (111) | SMART-Liver (51) | Standard care (60) | Self-tracking, education, coaching and SMS text messages | Weight reduction (P<0.001) BMI Reduction (P<0.001) liver fat score reduction (P=0.01) AST reduction (P=0.03) ALT reduction (P=0.002) ɣ-GT reduction (P=0.04) Self-regulation improvement (P<0.001) Depression improvement (P=0.003) Fatigue improvement (P=0.005) Quality of life scores improvement (P<0.001) |
(23) |
| Noom Weight | Jonathan et al. | 16-Week | Patients with NASH and a smartphone (40) | Noom Weight (20) | Standard care (20) | Self- tracking, feedback, education and motivation | Weight reduction (P = 0.008) BMI reduction (P = 0.037) AST reduction (P = 0.310) ALT reduction (P = 0.547) ALPs reduction (P = 0.838) NFS improvement (P = 0.444) FIB-4 improvement (P = 0.733) |
(24) |
| NASH app | Sato et al. | 48-Week | Patients with NASH or NAFLD (20) | NASH app (20) | _ | Advice, education, and counseling sessions | NASa reduction (P < 0.001) Weight reduction (P < 0.001) AST reduction (P = 0.001) ALT reduction (P < 0.001) ɣ-GT reduction (P = 0.02) ALPs reduction (P < 0.001) TG reduction (P = 0.01) Improvement in parameters related to insulin resistance (P > 0.05) |
(25) |
| Better Therapeutics app | Alkhouri et al. | 90-Day | Patients with MASLD or MASH (22) | Better Therapeutics app (22) | - | Digital therapeutic delivery, CBT, standardized lessons, personalized goal-setting, and self-monitoring | Weight reduction (P = 0.008) ALT reduction (P = 0.007) FIB-4 improvement (P = 0.045) |
(21) |
a. NAS: nonalcoholic fatty liver disease activity score.